Medicare’s second round of drug-price negotiations will set lower prices on 15 additional medications beginning January 1, 2027, and for the first time the program reaches beyond the pharmacy counter to drugs administered in a doctor’s office. The new list includes widely used treatments, among them the semaglutide products Ozempic and Wegovy. Federal analysts project billions of dollars in savings once the prices take hold. But the figures describe what the Medicare program pays, not automatically what a beneficiary hands over at the register, and that distinction shapes how much of the change any individual will feel.
A second round that adds 15 drugs
The negotiation authority lets Medicare set prices directly with manufacturers for a growing list of high-spending drugs, phased in over several years. According to KFF’s tracking of the program, the round taking effect in 2027 adds 15 more medicines on top of the first list, chosen from among the drugs on which Medicare and its enrollees spend the most. The selected treatments span chronic conditions common in older adults, and the inclusion of the semaglutide products reflects how much spending those medications now drive.
The prices are negotiated once and then apply across the program, so the effect is broad rather than plan-by-plan. That is different from a coupon or a manufacturer discount aimed at one group of patients. The point of the mechanism is to lower the baseline price Medicare recognizes for a drug, which in turn feeds into what plans and the program spend and, for some enrollees, into cost-sharing that is calculated off that price.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
Physician-administered drugs enter for the first time
The larger structural shift is that the 2027 round extends, for the first time, to drugs given in a clinical setting rather than filled at a pharmacy. Until now the program touched only Part D drugs, the ones a patient picks up and takes at home. Physician-administered treatments, the kind delivered by infusion or injection in a doctor’s office or clinic, fall under Part B and had been outside the program’s reach. The agency that runs the negotiations, CMS, confirms that expansion arrives with this round.
That matters because some of the most expensive treatments in Medicare are the ones administered in a clinical setting, where a single dose can carry a price far beyond a typical pharmacy prescription. Bringing those drugs into the negotiation for the first time widens the range of spending the program can address, and it changes the calculus for patients whose costliest treatments were never on the table before. It is the reason this round is described as a first, not simply a larger version of the last.
The expansion is a policy milestone rather than an overnight repricing of every clinic bill. Only the specific drugs selected for the round are affected, and the negotiated prices are the ones Medicare will recognize once they take effect. Treatments not on the list continue to be priced the way they were, so the change is real but bounded to the drugs the program named.
What it means for a beneficiary’s own costs
The savings headlines describe program-level spending, and the connection to any one person’s out-of-pocket cost is indirect. What a beneficiary pays depends on their plan’s cost-sharing structure, whether they have reached the plan’s out-of-pocket limit, and how the plan calculates a copay or coinsurance for a given drug. A lower negotiated price can flow through to a smaller coinsurance in some cases, but it does not guarantee that a fixed copay drops, and it is not a rebate mailed to enrollees.
For patients on the specific drugs named, the practical effect is likeliest to show up where cost-sharing is tied to a percentage of the drug’s price rather than a flat dollar amount. A member whose plan charges coinsurance on a negotiated drug could see that share shrink as the underlying price falls, while a member paying a set copay may notice little change at the counter even as the program spends less behind the scenes.
For a beneficiary who takes one of the named drugs, the concrete question is how their own plan prices that specific medication, because that is where a lower recognized price either flows through or stops. Two members on the identical drug can experience the change differently depending on whether their plans apply coinsurance or a flat copay, whether they have met the deductible, and how close they are to their annual out-of-pocket limit. The negotiated price is uniform across the program, but the personal result runs through the individual plan’s design, which is why the headline savings figure is a poor predictor of any one person’s bill.
The 2027 round, then, is best read as two things at once: a continued lowering of what Medicare pays for a widening list of drugs, and a first step into the clinical-drug spending that had been off-limits. Whether a given retiree feels it depends less on the headline savings figure than on the fine print of their own plan and the drugs they actually take.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
More Financial Reading
